Non-exclusive drug discount agreement for Axitinib
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Axitinib (ATC-Code nach WHO: L01EK01)
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase quantities; actual demand is unpredictable and dependent on patient numbers and prescriber behavior...
The buyer reserves the right to terminate the open-house model early if exclusive agreements are concluded. According t...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Conclusion of non-exclusive drug discount agreements for Axitinib (ATC L01EK01) under § 130a (8) SGB V.
- Open-house model: any eligible pharmaceutical company can enter into the agreement during the participation period.
Afficher le résumé complet
Non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a (8) SGB V for the active ingredient Axitinib (ATC L01EK01) via an open-house model. The buyer is AOK PLUS for the regions of Saxony and Thuringia. Participation is open to all interested pharmaceutical companies meeting the conditions. No guaranteed purchase quantities. The contract runs until 30 September 2026. First submission deadline: 5 August 2025; subsequent submissions accepted periodically. Submitted documents are confidential.
Risques
No minimum purchase quantities; actual demand is unpredictable and dependent on patient numbers and prescriber behavior...
The buyer reserves the right to terminate the open-house model early if exclusive agreements are concluded. According t...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical company as defined in § 4 (18) AMG for the offered medicinal products.
- Company must have its seat in Germany, another EU member state, or an EEA state (§ 9 (2) AMG).
Eligibility
- Must submit a declaration regarding non-exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Axitinib
One lot covering the conclusion of non-exclusive discount agreements for Axitinib. Scope includes pharmaceutical products with ATC code L01EK01. Performance location: Dresden, Germany.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
No explicit award criteria provided
the notice indicates this is an open-house model where the agreement is offered to all eligible participants under fixed conditions. The criteria are likely related to the offered discount rate, but details are only in the confidential project room documents.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Axitinib (ATC-Code nach WHO: L01EK01)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 14 Jul 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 459714-2025
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase quantities; actual demand is unpredictable and dependent on patient numbers and prescriber behavior...
The buyer reserves the right to terminate the open-house model early if exclusive agreements are concluded. According t...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications